Display search results for ** instead (47 products)

Showing 31-40 of 47

This Vital Signs issues trends in orphan drugs, genetic research apps, Thermo Fisher Scientific's acquisition of Affymetrix, and the Zika Virus.

USD 450.00

USD 337.50 save 25 %

04 Apr 2016  |  Global

Vital Signs - Emerging Trends and Opportunities in Life Sciences, February 2016

Exciting Developments in Generic Drug Pricing, CRISPR Technology, GenomeAsia 100K and Large-scale Next-generation Sequencing Projects, and Medicare Outcomes

This Vital Signs issues discusses generic drug pricing, CRISPR technology, GenomeAsia 100K and large-scale next-generation sequencing projects, and Medicare outcomes target.

USD 450.00

USD 337.50 save 25 %

12 Feb 2016  |  Global

Vital Signs - Impact of Strategic Acquisitions on Life Sciences Market, 2016

Portfolio Expansions Follow Acquisitions by Panasonic Healthcare Holdings Co.,Thermo Fisher Scientific and Abbott Laboratories

This Vital Signs issues discusses Panasonic Healthcare's completed acquisition of Bayer's Diabetes Care Unit, Thermo Fisher Scientific's acquisition of Affymetrix, several moves in the single cell-genomics market by Bio-Rad, Illumina, Qiagen, and 10x Genomics, and Abbott's acquisition of Alere.

USD 450.00

USD 337.50 save 25 %

04 Feb 2016  |  Global

Vital Signs - Spiraling US Drug Costs, Wearable Healthcare Technologies and the Zika Virus, An Analysis

Urgent Remedial Action Required as Nearly 1/4th US Prescription Drug Users Find it Difficult to Afford their Prescriptions

This issue of Vital Signs discusses why the US pays more than other countries for drugs, the inside story on wearable electronics, the spreading Zika virus, and soaring US drug costs.

USD 450.00

USD 337.50 save 25 %

As the New Year begins, the editorial team at the Manufacturing Leadership Council offers its predictions for the year ahead. Contributors to this blog include David R. Brousell, Jeff Moad, Sankara Narayanan, and Paul Tate.

USD 500.00

USD 375.00 save 25 %

05 Jan 2016  |  Global

Vital Signs - Advances in Cancer Treatment, Clampdown on Specialty Pharmacies and Strategy Revamp for Sequencing Provider, An Analysis

Liquid Biopsy Test for Prostate Cancer and Non-small Cell Lung Cancer Treatment Show Promise

This issue of Vital Signs discusses MDxHealth's launch of the SelectMDx Liquid Biopsy Test in Europe, the FDA's approval of a new treatment for non-small cell lung cancer with EGFR mutations, the clamp down on specialty pharmacies by US drug benefit managers, and BGI's strategy redirection for Complete Genomics.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs discusses the FDA's clearnace of the first 3-D printed prescription drug, Illumina's formation of consumer genomics company Helix, Response Genetics' acquisition of Cancer Genetics, and Roche's acquisition of GeneWEAVE.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on February 4, 2014, discusses Roches collaboration with Foundation Medicine, Novartis potential anti-aging drug, and DNA Electronics; acquisition of nanoMR, Inc.

USD 500.00

USD 375.00 save 25 %

This issue of Vital Signs, released on October 3, 2014, discusses Merck KGaAs acquisition of Sigma-Aldrich, highlights from the 2014 AACC Meeting, Abbotts CE Mark for FreeStyle® Libre, laboratory developed test (LDT) regulations, and the sale of Fortis Healthcares Singapore subsidiary, RadLink-Asia Pte Ltd, and its arm, RadLink Singapore.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on September 3, 2014, discusses Thermo Fisher Scientifics divestment of laboratory equipment company Cole-Parmer to GTCR, the increasing use of large animal biotechnology in human health applications, the collaboration of Life Technologies and RainTree Oncology Services, the agreement between Ventana and Quintile...

USD 450.00

USD 337.50 save 25 %

Showing 31-40 of 47